Recombinant full-length factor VIII (FVIII) and extended half-life FVIII products in prophylaxis - new insight provided by pharmacokinetic modelling

Haemophilia

Volumn 21, Issue 3, 2015, Pages 300-306

  Gringeri, A ^a   Wolfsegger, M ^a   Steinitz, K N ^a   Reininger, A J ^a  

^a BAXTER INNOVATIONS GMBH   (Austria)

Author keywords

Extended half life; Factor VIII; Haemophilia; Pharmacokinetics; Prophylaxis; Trough level

Indexed keywords

BLOOD CLOTTING FACTOR 8; RECOMBINANT FULL LENGTH FACTOR VIII; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR; RECOMBINANT PROTEIN;

AGE DISTRIBUTION; ARTICLE; BODY WEIGHT; DRUG CLEARANCE; HALF LIFE TIME; HEMATOCRIT; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MEAN RESIDENCE TIME; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; ADOLESCENT; ADULT; BLOOD; BLOOD CLOTTING; CHILD; MALE; MIDDLE AGED; PREMEDICATION; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD COAGULATION; BODY WEIGHT; CHILD; FACTOR VIII; HALF-LIFE; HEMATOCRIT; HEMOPHILIA A; HUMANS; MALE; MIDDLE AGED; PREMEDICATION; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84928823510     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12605     Document Type: Article

References (26)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44.
2. Gringeri A, Lundin B, von MS, Mantovani L, Mannucci PM. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
3. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol 1999; 105: 1109-13.
4. den Uijl IE, Fischer K, Van Der Bom JG, Grobbee DE, Rosendaal FR, Plug I. Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levels. Haemophilia 2011; 17: 41-4.
5. Skinner MW. WFH: closing the global gap-achieving optimal care. Haemophilia 2012; 18(Suppl. 4): 1-12.
6. Gringeri A., Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia 2014; 20: 459-63.
7. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl 1965; (Suppl. 77): 3-132.
8. Collins PW, Blanchette VS, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413-20.
9. Valentino LA, Collins PW, Pipe S et al. Peak FVIII levels and time spent in hemostatically effective FVIII range post-infusion correlates with improved efficacy for prophylaxis in hemophilia A: a closer look at the other end of the curve. J Thromb Haemost 2013; 11(Suppl. S2): 932-933. Abstract PB 4.39-1.
10. Collins PW, Bjorkman S, Fischer K et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
11. Food and Drug Administration (FDA). Guidance for industry. Population pharmacokinetics. 1999. Available at http://www.fda.gov/cber/gdlns/popharm.htm. Accessed September 16, 2014.
12. Peyvandi F, Garagiola I, Seregni S. Future of coagulation factor replacement therapy. J Thromb Haemost 2013; 11(Suppl. 1): 84-98.
13. Tarantino MD, Collins PW, Hay CR et al. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia 2004; 10: 428-37.
14. Powell JS, Josephson NC, Quon D et al. Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031-7.
15. Bjorkman S, Oh M, Spotts G et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612-8.
16. Neelakantan S, Li S, Powell J et al. Population pharmacokinetic analysis of long-lasting recombinant factor VIII Fc fusion protein (rFVIIIFc) in patients with severe haemophilia A. J Thromb Haemost 2013; 11(Suppl. S2): 354. Abstract PA 2.06-3.
17. tmvtnorm. Truncated multivariate normal and student t distribution [computer program]. Version R Package Version 1.4-8 2013. Available at http://cran.rproject.org/web/packages/tmvtnorm/tmvtnorm.pdf. Accessed September 16, 2014.
18. Gabrielsson J, Weiner D. Pharmacokinetic & pharmacodynamic data analysis: concepts and applications (4th edn). Stockholm, Sweden: Swedish Pharmaceutical Press, 2000.
19. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
20. Baxter Healthcare Corporation. ADVATE prescribing information. 2014. Available at http://www.baxter.com/downloads/healthcare_professionals/products/ADVATE_PI.pdf. Accessed September 16, 2014.
21. Biogen Idec Inc. ELOCTATE prescribing information. 2014. Available at http://eloctate.com/pdfs/full-prescribing-information.pdf. Accessed September 16, 2014.
22. Byers JP, Sarver JG. Pharmacokinetic modeling. In: Hacker M, Messer W, Bachmann K eds. Pharmacology: Principles and Practice. Burlington: Academic Press, 2009: 201-77.
23. R Foundation for Statistical Computing. R: A Language and Environment for Statistical Computing [Computer Program]. Vienna, Austria: R Foundation for Statistical Computing, 2013.
24. Valentino LA, Mamonov V, Hellmann A et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10: 359-67.
25. Lindvall K, Astermark J, Bjorkman S et al. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy. Haemophilia 2012; 18: 855-9.
26. Manco-Johnson MJ, Kempton CL, Reding MT et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.